Published in Cell Signal on February 12, 2010
Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Res (2011) 2.32
Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression. Cell Tissue Res (2011) 1.53
Characterization of type III TGF-β receptor expression in invasive breast carcinomas: a potential new marker and target for triple negative breast cancer. J Cell Commun Signal (2014) 1.39
The relevance of the TGF-β Paradox to EMT-MET programs. Cancer Lett (2013) 1.18
Dynamics of TGF-β/Smad signaling. FEBS Lett (2012) 1.12
TGFβ and BMP-2 regulate epicardial cell invasion via TGFβR3 activation of the Par6/Smurf1/RhoA pathway. Cell Signal (2011) 1.03
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest (2013) 1.02
Gene expression profiling suggests a pathological role of human bone marrow-derived mesenchymal stem cells in aging-related skeletal diseases. Aging (Albany NY) (2011) 1.00
Proteoglycans in prostate cancer. Nat Rev Urol (2012) 0.99
CCN6 knockdown disrupts acinar organization of breast cells in three-dimensional cultures through up-regulation of type III TGF-β receptor. Neoplasia (2012) 0.98
Heparan sulfate signaling in cancer. Trends Biochem Sci (2014) 0.97
Role of TGF-β and the tumor microenvironment during mammary tumorigenesis. Gene Expr (2011) 0.97
Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth. Neoplasia (2011) 0.96
BMP2 signals loss of epithelial character in epicardial cells but requires the Type III TGFβ receptor to promote invasion. Cell Signal (2012) 0.95
TGF-β induces TIAF1 self-aggregation via type II receptor-independent signaling that leads to generation of amyloid β plaques in Alzheimer's disease. Cell Death Dis (2010) 0.95
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood (2013) 0.92
Plum, an immunoglobulin superfamily protein, regulates axon pruning by facilitating TGF-β signaling. Neuron (2013) 0.91
Biological functions of iduronic acid in chondroitin/dermatan sulfate. FEBS J (2013) 0.91
Endocardial cell epithelial-mesenchymal transformation requires Type III TGFβ receptor interaction with GIPC. Cell Signal (2011) 0.87
The Role of TGF-β Receptors in Fibrosis. Open Rheumatol J (2012) 0.87
Control of organization and function of muscle and tendon by thrombospondin-4. Matrix Biol (2014) 0.86
Dab2 inhibits the cholesterol-dependent activation of JNK by TGF-β. Mol Biol Cell (2014) 0.83
Coated pit-mediated endocytosis of the type I transforming growth factor-β (TGF-β) receptor depends on a di-leucine family signal and is not required for signaling. J Biol Chem (2012) 0.83
Synovial expression of Th17-related and cancer-associated genes is regulated by the arthritis severity locus Cia10. Genes Immun (2011) 0.82
Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma. J Clin Invest (2013) 0.80
Omics for prediction of environmental health effects: Blood leukocyte-based cross-omic profiling reliably predicts diseases associated with tobacco smoking. Sci Rep (2016) 0.80
Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy. Front Immunol (2014) 0.80
A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients. Cancer Biol Ther (2015) 0.80
Regulation of TGF-β receptor hetero-oligomerization and signaling by endoglin. Mol Biol Cell (2015) 0.79
TRAF6 mediates IL-1β/LPS-induced suppression of TGF-β signaling through its interaction with the type III TGF-β receptor. PLoS One (2012) 0.79
The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells. Neoplasia (2014) 0.79
Chemotherapeutic Targeting of the Transforming Growth Factor-β Pathway in Breast Cancers. Breast Cancer Manag (2015) 0.79
Transient overexpression of TGFBR3 induces apoptosis in human nasopharyngeal carcinoma CNE-2Z cells. Biosci Rep (2013) 0.79
Simvastatin alleviates cardiac fibrosis induced by infarction via up-regulation of TGF-β receptor III expression. Br J Pharmacol (2015) 0.79
The role of transforming growth factor-beta in suppression of hepatic metastasis from colon cancer. HPB (Oxford) (2010) 0.77
Betaglycan (TβRIII) is expressed in the thymus and regulates T cell development by protecting thymocytes from apoptosis. PLoS One (2012) 0.77
The type III TGFβ receptor regulates filopodia formation via a Cdc42-mediated IRSp53-N-WASP interaction in epithelial cells. Biochem J (2013) 0.77
Functional role of TGF-β receptors during palatal fusion in vitro. Arch Oral Biol (2014) 0.76
Cell-penetrating peptides selectively targeting SMAD3 inhibit profibrotic TGF-β signaling. J Clin Invest (2017) 0.76
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Invest New Drugs (2014) 0.75
Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling. J Biol Chem (2016) 0.75
c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol (2014) 0.75
Endoglin is necessary for angiogenesis in human ovarian carcinoma-derived primary endothelial cells. Cancer Biol Ther (2013) 0.75
TβRIII independently binds type I and type II TGF-β receptors to inhibit TGF-β signaling. Mol Biol Cell (2015) 0.75
High FMNL3 expression promotes nasopharyngeal carcinoma cell metastasis: role in TGF-β1-induced epithelia-to-mesenchymal transition. Sci Rep (2017) 0.75
Overexpression of transforming growth factor type III receptor restores TGF-β1 sensitivity in human tongue squamous cell carcinoma cells. Biosci Rep (2015) 0.75
Serum inhibin A and inhibin B levels in epithelial ovarian cancer patients. PLoS One (2014) 0.75
TGF-β cascade regulation by PPP1 and its interactors -impact on prostate cancer development and therapy. J Cell Mol Med (2014) 0.75
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94
TGF-beta signal transduction. Annu Rev Biochem (1998) 17.83
TGFbeta in Cancer. Cell (2008) 17.44
Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer (2006) 8.59
Mechanism of activation of the TGF-beta receptor. Nature (1994) 8.10
TGF-beta-induced epithelial to mesenchymal transition. Cell Res (2009) 7.88
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res (2006) 4.11
Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev (2005) 4.05
Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol (2009) 3.94
TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J (2002) 3.80
Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta (2006) 3.64
Role of transforming growth factor Beta in human cancer. J Clin Oncol (2005) 3.53
Betaglycan presents ligand to the TGF beta signaling receptor. Cell (1993) 3.48
Renal cell carcinoma guideline. Eur Urol (2007) 3.42
TGF-beta and cancer. Cytokine Growth Factor Rev (2005) 3.38
Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev (2006) 3.14
Expression cloning and characterization of the TGF-beta type III receptor. Cell (1991) 2.89
TGF-beta signaling: a tale of two responses. J Cell Biochem (2007) 2.83
Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell (1991) 2.73
Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science (1999) 2.72
Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta (2008) 2.72
Metastasis mechanisms. Biochim Biophys Acta (2009) 2.51
Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells. Br J Cancer (2005) 2.37
New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol (2009) 2.34
Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science (2003) 2.31
Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature (2000) 2.17
Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. Genes Dev (1993) 2.13
The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest (2006) 2.06
Different routes of bone morphogenic protein (BMP) receptor endocytosis influence BMP signaling. Mol Cell Biol (2006) 1.99
Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta. J Cell Biol (1989) 1.97
Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines. J Biol Chem (1985) 1.96
Cellular distribution of type I and type II receptors for transforming growth factor-beta. J Biol Chem (1986) 1.82
A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. J Biol Chem (2001) 1.77
Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. J Biol Chem (2008) 1.71
Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer (1999) 1.71
The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res (2007) 1.65
The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta (2009) 1.61
Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol (1994) 1.59
Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. Mol Cell Biol (2003) 1.59
Spatial and temporal patterns of immunoreactive transforming growth factor beta 1, beta 2, and beta 3 during excisional wound repair. Am J Pathol (1993) 1.52
Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis (2007) 1.51
The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci U S A (2009) 1.49
The transforming growth factor-beta receptor type III is a membrane proteoglycan. Domain structure of the receptor. J Biol Chem (1988) 1.47
Transforming growth factor-alpha and beta-amyloid precursor protein share a secretory mechanism. J Cell Biol (1995) 1.46
Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer (2005) 1.42
Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res (2002) 1.31
Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Res (2007) 1.30
TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis (2008) 1.28
Subunit structure of a high-affinity receptor for type beta-transforming growth factor. Evidence for a disulfide-linked glycosylated receptor complex. J Biol Chem (1985) 1.28
Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling. J Biol Chem (2001) 1.26
The soluble exoplasmic domain of the type II transforming growth factor (TGF)-beta receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-beta ligands. J Biol Chem (1995) 1.25
Inhibin is an antagonist of bone morphogenetic protein signaling. J Biol Chem (2002) 1.24
Coronary vessel development is dependent on the type III transforming growth factor beta receptor. Circ Res (2007) 1.22
Binding of two growth factor families to separate domains of the proteoglycan betaglycan. J Biol Chem (1992) 1.20
Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis (2008) 1.17
Autocrine TGFbeta supports growth and survival of human breast cancer MDA-MB-231 cells. Oncogene (2002) 1.16
Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene (2002) 1.16
Transforming growth factor-(beta)s and mammary gland involution; functional roles and implications for cancer progression. J Mammary Gland Biol Neoplasia (2009) 1.15
Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene (2003) 1.15
A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res (1999) 1.13
Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions. J Biol Chem (2006) 1.13
Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J Biol Chem (2001) 1.13
TGFBR3 loss and consequences in prostate cancer. Prostate (2007) 1.12
Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol (2005) 1.12
Localization of transforming growth factor beta binding site in betaglycan. Comparison with small extracellular matrix proteoglycans. J Biol Chem (1993) 1.11
Endocytosis of the type III transforming growth factor-beta (TGF-beta) receptor through the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptor down-regulation. J Biol Chem (2008) 1.09
The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1. J Biol Chem (2003) 1.07
Transforming growth factor-beta pathway: role in pancreas development and pancreatic disease. Cytokine Growth Factor Rev (2005) 1.06
The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. Carcinogenesis (2007) 1.06
Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. Biochem J (2001) 1.06
Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2. J Biol Chem (1995) 1.05
Elevated expression of TGF-beta1 in head and neck cancer-associated fibroblasts. Mol Carcinog (2004) 1.04
Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cell Signal (2009) 1.04
Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer (1997) 1.04
TGFbeta Type III and TGFbeta Type II receptors have distinct activities during epithelial-mesenchymal cell transformation in the embryonic heart. Dev Dyn (2001) 1.04
Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility. J Biol Chem (2007) 1.03
Cell-surface co-receptors: emerging roles in signaling and human disease. Trends Biochem Sci (2005) 1.02
The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2. Carcinogenesis (2009) 1.02
Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J Biol Chem (2001) 1.02
Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate (2005) 1.01
Regulation of TGF-beta ligand and receptor expression in neonatal rat lungs exposed to chronic hypoxia. J Appl Physiol (1985) (2002) 1.00
Molecular cloning and characterization of the human and porcine transforming growth factor-beta type III receptors. Biochem Biophys Res Commun (1992) 0.99
Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. Carcinogenesis (2008) 0.99
Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J Biol Chem (1997) 0.99
Betaglycan induces TGF-beta signaling in a ligand-independent manner, through activation of the p38 pathway. Cell Signal (2006) 0.98
Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate. Prostate (1997) 0.96
Betaglycan has multiple binding sites for transforming growth factor-beta 1. Biochem J (1996) 0.95
Soluble betaglycan reduces renal damage progression in db/db mice. Am J Physiol Renal Physiol (2006) 0.95
Purification of the transforming growth factor-beta (TGF-beta) binding proteoglycan betaglycan. J Biol Chem (1991) 0.94
The TGF-beta type III receptor is localized to the medial edge epithelium during palatal fusion. Int J Dev Biol (2000) 0.94
Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III. Cell Growth Differ (1999) 0.93
The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors. Mol Biol Cell (2009) 0.92
Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Res (2008) 0.92
Mapping of the ligand binding domain of the transforming growth factor beta receptor type III by deletion mutagenesis. Proc Natl Acad Sci U S A (1994) 0.92
Cloning the promoter for transforming growth factor-beta type III receptor. Basal and conditional expression in fetal rat osteoblasts. J Biol Chem (1999) 0.90
Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells. Mol Endocrinol (2009) 0.89
Type III transforming growth factor-beta (TGF-beta) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-beta signaling pathway. Clin Cancer Res (2008) 0.88
Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol Cancer Res (2005) 0.88
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
Role of transforming growth factor Beta in human cancer. J Clin Oncol (2005) 3.53
Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta (2008) 2.72
Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Res (2011) 2.32
Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science (2003) 2.31
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood (2010) 2.15
The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest (2006) 2.06
T cell factor 1 initiates the T helper type 2 fate by inducing the transcription factor GATA-3 and repressing interferon-gamma. Nat Immunol (2009) 1.99
Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. J Biol Chem (2008) 1.71
The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res (2007) 1.65
Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades. J Biol Chem (2002) 1.58
Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis (2007) 1.51
The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci U S A (2009) 1.49
Role of transforming growth factor-beta in hematologic malignancies. Blood (2006) 1.41
The clinical course and genetic defect in the PCFT gene in a 27-year-old woman with hereditary folate malabsorption. J Pediatr (2008) 1.36
Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Res (2007) 1.30
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys (2007) 1.28
TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis (2008) 1.28
Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J Biol Chem (2008) 1.27
IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J Immunol (2011) 1.25
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol (2006) 1.21
Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis (2008) 1.17
Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-beta signaling at the bipotent erythro-megakaryocytic progenitor stage. Blood (2010) 1.16
The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells. J Biol Chem (2007) 1.12
Endocytosis of the type III transforming growth factor-beta (TGF-beta) receptor through the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptor down-regulation. J Biol Chem (2008) 1.09
The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. Carcinogenesis (2007) 1.06
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist (2011) 1.05
Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cell Signal (2009) 1.04
Cell-surface co-receptors: emerging roles in signaling and human disease. Trends Biochem Sci (2005) 1.02
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest (2013) 1.02
The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. Carcinogenesis (2009) 1.02
ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration. Carcinogenesis (2009) 1.02
The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2. Carcinogenesis (2009) 1.02
Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells. EMBO J (2012) 1.02
Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. Carcinogenesis (2008) 0.99
Endoglin regulates PI3-kinase/Akt trafficking and signaling to alter endothelial capillary stability during angiogenesis. Mol Biol Cell (2012) 0.98
Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth. Neoplasia (2011) 0.96
The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol Biol Cell (2011) 0.95
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res (2011) 0.95
Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB J (2013) 0.95
Tyrosine phosphatase SHP-1 in oxidative stress and development of allergic airway inflammation. Am J Respir Cell Mol Biol (2008) 0.94
BMP-2 and TGFβ2 shared pathways regulate endocardial cell transformation. Cells Tissues Organs (2011) 0.93
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother Pharmacol (2010) 0.93
The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors. Mol Biol Cell (2009) 0.92
Molecular characterization of the tumor-suppressive function of nischarin in breast cancer. J Natl Cancer Inst (2011) 0.92
Casein kinase 2beta as a novel enhancer of activin-like receptor-1 signaling. FASEB J (2009) 0.92
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res (2013) 0.91
SHP-1 deficient mast cells are hyperresponsive to stimulation and critical in initiating allergic inflammation in the lung. J Immunol (2009) 0.90
Spontaneous eosinophilic nasal inflammation in a genetically-mutant mouse: comparative study with an allergic inflammation model. PLoS One (2012) 0.87
Endocardial cell epithelial-mesenchymal transformation requires Type III TGFβ receptor interaction with GIPC. Cell Signal (2011) 0.87
TRPA1-dependent pruritus in IL-13-induced chronic atopic dermatitis. J Immunol (2013) 0.87
Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy. Expert Opin Biol Ther (2003) 0.87
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.86
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer (2011) 0.84
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Invest New Drugs (2013) 0.84
The type III TGFbeta receptor regulates directional migration: new tricks for an old dog. Cell Cycle (2009) 0.83
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. Invest New Drugs (2014) 0.82
A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. Cancer Med (2013) 0.82
Tyrosine phosphatase SHP-1 in allergic and anaphylactic inflammation. Immunol Res (2010) 0.81
Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma. J Clin Invest (2013) 0.80
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. Anticancer Res (2010) 0.80
Regulation of ALK-1 signaling by the nuclear receptor LXRbeta. J Biol Chem (2002) 0.80
Implication of lymph node metastasis detected on 18F-FDG PET/CT for surgical planning in patients with peripheral intrahepatic cholangiocarcinoma. Clin Nucl Med (2014) 0.79
SHP-1 regulation of mast cell function in allergic inflammation and anaphylaxis. PLoS One (2013) 0.78
Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. J Clin Invest (2014) 0.78
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. Oncologist (2013) 0.78
Erratum to: angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction. J Mol Med (Berl) (2015) 0.77
The type III TGFβ receptor regulates filopodia formation via a Cdc42-mediated IRSp53-N-WASP interaction in epithelial cells. Biochem J (2013) 0.77
Effect of acellular dermal matrix as a delivery carrier of adipose-derived mesenchymal stem cells on bone regeneration. J Biomed Mater Res B Appl Biomater (2012) 0.77
Angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction. J Mol Med (Berl) (2014) 0.76
A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys (2006) 0.75
Synthesis of antifungal evaluation of 2H-[1,2,3]Triazolo[4,5-g]isoquinoline-4,9-diones. Chem Pharm Bull (Tokyo) (2014) 0.75
Synthesis of benzofuro[6,7-d]thiazoles, benzofuro[7,6-d]thiazoles and 6-arylaminobenzo[d]thiazole-4,7-diones as antifungal agent. Chem Pharm Bull (Tokyo) (2014) 0.75